In Competitive RSV Market, GSK Aims To Be First For Adults 50-59

 
• By Jessica Merrill and Sarah Karlin-Smith
  
building blocks
GSK is hoping to build out the label for its RSV vaccine • Source: Shutterstock

More from Anti-infective

More from Therapy Areas